Under Q3 guidelines ... Investor Presentation Jan '24
One-off (H2 FY24) decrease in expected revenue from TELA Bio, Inc. (‘TELA Bio’) due to a previous
overestimation of AROA’s revenue share (non-cash) on inventory supplied to TELA Bio and a delay
to a joint product development project. OviTex and OviTex PRS remain on a strong growth
trajectory.
So ... couple of assumptions ... Q4, FY24 end, and end FY24 is March 31 so we'll get the H2 FY24 financial report in a week or so. Right?
Given the state of the general market the news is probably bad (on face value) so perhaps a washout coming.
Under Q3 guidelines ... Investor Presentation Jan '24One-off (H2...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.045(9.00%) |
Mkt cap ! $187.5M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 55.0¢ | 50.0¢ | $315.3K | 584.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 900 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 41500 | 2 |
View Market Depth
| Last trade - 15.58pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
54.0¢ |
Change
0.045 ( 5.88 %) |
||||
| Open | High | Low | Volume | ||
| 50.5¢ | 54.5¢ | 50.5¢ | 41117 | ||
| Last updated 15.44pm 03/05/2024 ? | |||||
| ARX (ASX) Chart |